The pharmacokinetics of 80 mg frusemide given orally were investigated in normal subjects using a direct HPLC method for parent drug and its acyl glucuronide conjugate.
Frusemide
(4-chloro-Af-(2"furylmethyl)-5-sulphamoylanthranilic acid, pKa 3*9) inhibits the active reabsorption of chloride ions in the thick ascending limb of the loop of líenle by binding to one of the Cl-binding sites of the NaH / 2C1"/K+ co-transport system. In man, frusemide is meta bolized to its acyl glucuronide (Beerman et al 1975 (Beerman et al , 1977 . Acyl glucuronides are unstable in alkaline media (pH > 7*0); therefore, for analysis urine must be kept acidic at pH 5*0 in order to prevent hydrolysis and isomerization of acyl glu curonides even before excretion (Faed 1984; Rachmel et ai 1985; Vree et al 1992a Vree et al , 1993a .
The reported half-lives (ti) of frusemide and its glucuronide are of the order of 2h (Hammarlund et al 1985; Vree et al 1994 Vree et al , 1995b . In a pilot experiment in our laboratory, a second, long half-life of frusemide and its acyl glucuronide became visible (Vree et al 1994) . Hammarlund et al (1985) mentioned the effect of an acute tolerance to frusemide's effect as being a homeostatic adap tive response to the acute loss of salt or water. This homeo static response, which Reyes called a rebound effect (Reyes 1991) , may also be the result of a prolonged disposition of frusemide at the Cl-binding sites.
The aim of this investigation was to study the pharmaco kinetics of frusemide and its acyl glucuronide in healthy volunteers, to assess the long half-life of parent drug and glucuronide conjugate, and to analyse the diuretic and antidiuretic response.
Drugs and chemicals
Frusemide and Lasix (40 mg tablets) were obtained from Hoechst (Amsterdam, Netherlands and Frankfurt, Ger many). All other reagents were of analytical grade and obtained from Merck (Darmstadt, Germany).
Frusemide acyl glucuronide was isolated and identified in human urine after administration of 80 mg frusemide (Vree et al 1994) .
Subjects
Seven human subjects (4 males (non-smokers), 3 females (one smoker), mean age 34 ± 7 years, mean bodyweight 80 ± 6 kg) participated in the study. The volunteers took 80 mg frusemide orally (as Lasix) after an overnight fast. The study had the approval of the hospital ethics committee, and informed consent was obtained from the volunteers.
Sampling
Fingertip blood samples (2mL), obtained with Monolet lancets (Monoject, St Louis, USA), were collected in heparinized Eppendorf vials (2 mL) at regular time intervals during 72 h following drug administration. After centrifugation, plasma samples were stored at -20°C pending analysis.
Urine was collected upon untimed voiding. The total time of sample collection was 96 h. Urinary pH was kept acidic (pH 5*0-5-5) by the oral intake of 1 g ammonium chloride four times per day (Ammonchlor, Siidmedica, Munich, Germany). Four urine samples of 5mL from each void were immediately stored at -20"C pending analysis. Total sampling time of urine was 96 h.
Each urine void (200-400 mL) was followed by ingestion of 100 mL water during the first period of 6h.
Drug analysis
Frusemide and its acyl glucuronide were assayed by HPLC as reported elsewhere (Vree et al 1994) . The limit of quanti tation of frusemide in plasma was 7 ngm L"1, and for the glucuronide 10 ngm L-'1. The limits of quantitation in urine were 100 and 150 ngmL 1 for the parent drug and glucuronide, respectively.
The intra-and interday variation of frusemide and glucuronide in plasma and urine was <5% . Recovery of frusemide after deproteinization of plasma was 91*5 ± 5-1 %, and that of the glucuronide was 85'5d:4*7%.
Plasma samples (100 /¿L) were deproteinized with 100 \CL acetonitrile and centrifuged at 3000#; 20 /¿L of the super natant was injected onto the column. The plasma samples were immediately injected onto the column. A stability test has shown that the glucuronide was stable at pH 7*4 for only 30 min.
Urine samples were diluted with an equal volume of water, and 20/¿L of that mixture was injected onto the column. The sample tray of the autosampler was protected from light.
Plasma binding
The in-vivo protein binding of frusemide and glucuronide was measured in volunteer plasma samples by means of the 100-, 10-: 
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Data analysis
Curve fitting was carried out (r2 >0*97), and the pharma cokinetic parameters of the plasma concentration-time curves, renal excretion rate-time profiles, and urine flow time profiles were calculated using the MediWare computer program (Proost & Meyer 1992) . Areas under the concen tration-time curves (AUC) were determined by the linear trapezoidal rule. Oral clearance (CL0) and mean residence time (MRT) were calculated by standard methods (Proost & Meyer 1992) . The renal clearance during the appropriate period was calculated by dividing the amount excreted in the urine during this period by the corresponding AUC value. Nonrenal clearance was defined as the oral clearance minns the renal clearance.
Recovery-, or rebound-time of the urine flow was defined as the time elapsed between the end of the urine flow stimulation at which the urine flow was < 1 m Lm in^1 and the time at which the urine flow reached again the value of > 1 mLmin" 1.
Analysis of variance was carried out by standard proce dures, and statistical difference was defined at P<0-05.
Results
Fig . I shows the plasma concentration-time curves and renal excretion rate-time profiles of frusemide and its acyl glucur onide in one representative subject, in which the slow elimination phase is visible in both the plasma and urine curves. Table I summarizes pharmacokinetic parameters of fru semide in plasma and Table 2 , the parameters in urine, Frusemide is quickly absorbed as can be concluded from the small values of tj8g, tmax, and t x A of absorption. The lag time in blood for frusemide is 0-29 ± 0* 16 h and of frusemide acyl glucuronide 0*32 ±0-24 h, (P=1*0). Both compounds were also quickly excreted; the t[ag of the compounds in urine do not differ significantly and did not differ from those in plasma.
Two half-lives (a and ¡3) can be distinguished , in the plasma elimination of both frusemide and its conjugate.
The t{a values of frusemide and its acyl glucuronide were 1 *25 =b0*75 and 1*31 ± 0 -6 0 h, respectively, which are not significantly different.
The plasma concentration-and renal excretion rate-time curves run parallel, resulting in similar values of the calcu lated pharmacokinetic parameters; plasma and urine t^ values of frusemide are respectively 33-2±28-0 and 29-7 ± 21*9 h. The corresponding values for frusemide acyl glucuronide are 30*4i 11'5 and 29*9 ± 2 0 '2h.
Although the long elimination half-life of frusemide and its acyl glucuronide in plasma was visible in five out of the seven volunteers, it was clearly visible in the urinary excre tion curves of all volunteers (29*7 ± 21'9 h, CV = 73*7%). The large coefficient of variation was caused by two volunteers showing extremely long half-lives of 37*8 h and 73-7 h (mean 55*8 ± 25*4 h; CV = 45.5%). The other five volunteers showed a much more consistent half-life of 16*4rL 1 *94h (11-8%).
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For frusemide acyl glucuronide the mean half-life in urine was 29*9 ± 20*2h (67*6%). The great variation was caused by three volunteers showing long half-lives of 37*8, 54*4, and 58*6h (50*3±11*0h; 21*9%). The other four volunteers showed a relatively short half-life of 14*6 ± 2-63 h (18-0%).
Protein binding
The protein binding of frusemide (98-0 ±2*0%) is signifi cantly higher than that of the acyl glucuronide (96* 1 ± 2*0%, P = 0*0284).
Percentage of the dose excreted in the urine
The main compound in the urine was frusemide. The renal excretion rate-time profile showed two phases, the rapid elimination phase lasting from 0-15h, and the second, slow phase from 15-96 h, During the first 15 h, frusemide excreted accounted for 33*3 ±4*8% of the dose; in the remaining 15-96-h period, 4*6 ±1*5% was excreted. In the same two periods, the percentage frusemide acyl glucuronide excreted was 13*4±4*7%, and 1*9±1*1%, respectively. In total, 46*7 ± 8*3% was excreted during the first 15h, and 6-4 ±2*1% during the remaining 15-96-h period. During the entire period (96 h), 53*0 ±7*2% of the dose was recov ered from the urine.
Renal clearance
The mean renal clearance of frusemide was calculated for the two elimination phases and was found to be 90*2± 16*9mLmin~l during the first period (0-15h), and 91*5±29*3mLmin~t during the remaining 15-96 h period, 64-7 ± 14-4 Urine production (mL)* 0-6 h + 2260*0 ± 755 0-0014** 6-96 h -990*0 ± 2 9 4 *Urine production exceeding the baseline value of 1 raLmin"1. **P value, difference between the two periods of urine produc tion. teff?ct, trcbound, time course of the effect. Um nx maximal urine production.
in which there was no stimulation of urine production. The clearance values in both periods were similar (P> 0*8) ( Table 1) .
The renal clearance of the acyl glucuronide was 702 ± 221 mLmin-1 in the first period but significantly decreased to 109 ± 51*0 mLmin-1 in the second period (P = 0*0083).
Urine production
The stimulated urine production in the first 6 h after admin istration amounted to 2260 ± 155 mL (measured urine pro duction minus baseline value of 1 mLmin"1 (360mL) ( Table 3) .
During the second or rebound period of 6-96 h after drug administration the average urine production was 990±294m L lower than what would have been expected from the baseline production of 5400 mL. This reduced production is equivalent to an 18% reduction in the baseline urine flow rate of 1 m Lm in"1 (0*82 mLmin-1).
The recovery-or rebound-time of the urine flow lasted 64-7 ± 14*4 h (CV = 22*3%). Table 4 compares the plasma concentration and renal excretion rates of frusemide and its glucuronide at the onset and end of stimulation of the urine production.
Discussion

Pharm acokinetics
This study shows that frusemide and its acyl glucuronide exhibit two half-lives. The short half-life of approximately 2 h is well known and related to the pharmacodynamic effect of the stimulation of the overall urine production. The second half-life of approximately 20-30 h has not been reported previously. During this slow elimination phase, only 4*6 ± 1-5% of the administered dose is excreted, which is 14% of the amount excreted during the first 15 h.
During the first phase, 13*4% of the acyl conjugate is excreted, and during the second phase, only 1*9 ±1*1%, which is 14% of the first phase and the same percentage reported for frusemide.
The short t}a values of frusemide and its acy! glucuronide in plasma give rise to the assumption that both compounds are excreted by glomerular secretion plus active tubular secretion. Indeed, the apparent renal clearance of frusemide was 90mLmin"1, which is similar during the first and second phases of elimination.
The apparent renal clearance value of the acyl glucuronide is high during the first phase (0-6 h; 702 ± 221 m Lmin-1) and lower in the second phase (109 ± 51*0m Lm in"1). In the second phase, the renal clearance values of frusemide and its acyl glucuronide are similar. The extreme high renal clearance of the acyl glucuronide during the first phase may be the result of hepatic and renal formation of the glucuronide (Smith & Benet 1983; Vree et al 1992a, b) ; the latter ceased in the second phase of the elimination. Probenecid inhibits the renal clearance of both frusemide (Chennavasin et al 1979; Smith et al 1980; Vree et al 1995b) and its acyl glucuronide (Vree et al 1995b) .
The relation between stimulation of the urine production and the renal formation of the acyl glucuronide may be coincidental, or it may indicate that the pharmacodynamic effect is the result of the action of the renal acyl glucuronide.
Onset and offset o f the effect
The pharmacodynamic activity of frusemide is believed to be produced as follows. The compound passes the kidney (in the thick ascending part of Henle's loop), until its concen tration or excretion rate reaches 21 ^gm in-1 (Koajarern et al 1982) ; the reabsorption of the Cl" ions is inhibited, resulting in a decrease in water reabsorption and increase in overall urine flow.
Indeed, as soon as frusemide and its acyl glucuronide appear in the urine after a similar lag time, the urine flow increases. Table 4 shows that in our group of subjects, a frusemide renal excretion rate of 28*0 ± 2*9 (Mg min-1 (10*4 %CV) in the T0M B-VREE ET AL elimination phase of the kinetic curve is correlated with the end of the stimulation of the urine production. The corre sponding excretion rate of the acyl glucuronide is 19-0 ± 10*8/¿gmin"1 (CV^56*8%). During the onset of the pharmacodynamic effect, the processes occur much faster, producing a larger coefficient of variation. For the first urine sample, the average urine production is already 8-0 ±4-6 mLmin"1 (57*5%) with a frusemide excretion rate of 62-9±58-l pgmin-1 (92-6%) and an acyl glucuronide value of 14*9± 14*2//gmin"1 (94*8%). Strikingly, the phar macodynamic effect starts and ends with excretion rates for the acyl glucuronide that do not differ (P = 0*50). The large difference and coefficients of variation of the excretion rates of frusemide in the first urine sample and onset of the pharmacodynamic effect makes the difference between onset and end of effect not statistically different. Similar data can be derived for the plasma concentration of parent compound and metabolite and the start and end of the urine flow stimulation (Table 4) .
A great difference is observed between frusemide plasma concentration at onset and end of the urine flow stimulation (P -0.0014). This is not observed for the frusemide acyl glucuronide for which the concentrations are not signifi cantly different (P = 0.55).
The stimulation of the urine production faded (< 1 mLmin"1) when the renal excretion rate of frusemide drops below the threshold of 20 ¿¿gmin"1, as reported by Koajarern et al (1982) . During the absorption phase, this value was already achieved in the second urine sample within 1 h of oral administration. The onset looks like an instantaneous maximum effect for an 80-mg dose.
Rebound
The pharmacodynamic effect-time curve shows a biphasic character. First, there is binding to one of the Cl~ binding sites of the Na+/2C1"/K+ co-transport system of the thick ascending part of the loop of Henle, resulting in an increase of the urine production greater than 1 mLmin"1 (Greger & Schlatter 1983; Wittner et al 1991; Swan 1994) , A rebound phase follows in which the urine production is less than the baseline value of 1 mLmin"1.
During the pharmacodynamic effect, 2260 ± 755 mL was excreted above the baseline value of 1 mLmin"1 for the unmedicated and well-hydrated subjects. Despite the fact that the subjects maintained their normal drinking and eating patterns, during this excess urine excretion period, it took three days for the body to regain this amount of fluid. The average urine production over those three days was 990 ± 294 mL less than what would have been excreted with the baseline value of 1 mLmin"1.
The baseline urine production of 1 mLmin"1 (= 1440mL in 24) was taken as a conservative estimate; the subjects showed values of 1-2mLmin"1 in other long-lasting phar macokinetic experiments with naproxen (Vree et al 1993a, b) and sulphamethoxazole (Vree et al 1995a) .
This time course of the rebound effect was subjectively felt to be three days, as experienced by the same subjects in other, short-term, frusemide experiments (Vree et al 1995b) . Therefore, the urine production was measured for four days in order to find an empiric measure for the restoration of the baseline value. The recovery time was found to be 65 h, and the total time of urine flow stimulation plus recovery time was 6h + 65 h = 71 h (3 days). The reported 24-h recovery period reported by Reyes (1991) was based on a collection period of only 24 h.
During this recovery period, frusemide and its acyl glu curonide were slowly eliminated from the body with a long half-life of 20-30 h for this phase. This recovery period was named acute tolerance to frusemide diuresis in man (Hammarlund et al 1985) ; rebound effects were named by Reyes (1991) . This recovery or rebound period coincides with the t^ of 20-30 h for both frusemide and its acyl glucuronide.
The rebound effect may be the result of a biphasic effect of frusemide or its acyl glucuronide. In concentrations or renal excretion rates > 20 ¿¿gmL"1, there is a stimulation of the urine production, while at concentrations below this thresh old there exists an inhibition of the urine production. These low renal excretion rates may exist in the slow elimination phase after administration of a therapeutic dose of 40-80 mg or higher dose, or they can be obtained after admin istration of 5 mg frusemide four times a day. The urine production under this low frusemide dosing regimen should be compared with baseline values of urine production in each patient or volunteer. When this was carried out in a pilot experiment, no inhibition of urine production was detected.
Clinical impliedtions
Cumulation of the frusemide plasma concentrations, due to the slow elimination phase, and cumulation of the rebound or recovery phase may induce a braking of the therapeutic or pharmacodynamic effect (Brater 1991) ,
